Next Article in Journal
A Canadian National Expert Consensus on Neoadjuvant Therapy for Breast Cancer: Linking Practice to Evidence and Beyond
Previous Article in Journal
Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue s1
10.3747/co.22.2360
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines

by
A.A. Joy
1,
M. Ghosh
1,
R. Fernandes
2 and
M.J. Clemons
2,*
1
Department of Oncology, Division of Medical Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
2
Division of Medical Oncology, University of Ottawa and The Ottawa Hospital Research Institute, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(s1), 29-42; https://doi.org/10.3747/co.22.2360
Submission received: 12 December 2014 / Revised: 14 January 2015 / Accepted: 11 February 2015 / Published: 1 March 2015

Abstract

Despite advancements in the treatment of early-stage breast cancer, many patients still develop disease recurrence; others present with de novo metastatic disease. For most patients with advanced breast cancer, the primary treatment intent is noncurative—that is, palliative—in nature. The goals of treatment should therefore focus on maximizing symptom control and extending survival. Treatments should be evaluated on an individualized basis in terms of evidence, but also with full respect for the wishes of the patient in terms of acceptable toxicity. Given the availability of extensive reviews on the roles of endocrine therapy and HER2 (human epidermal growth factor receptor 2)–targeted therapies for advanced disease, we focus here mainly on treatment guidelines for the non-endocrine management of HER2-negative advanced breast cancer in a Canadian health care context.
Keywords: Advanced breast cancer; metastatic breast cancer; treatment guidelines; her2-negativity; endocrine-resistant breast cancer; chemotherapy; targeted therapy; biologic therapy Advanced breast cancer; metastatic breast cancer; treatment guidelines; her2-negativity; endocrine-resistant breast cancer; chemotherapy; targeted therapy; biologic therapy

Share and Cite

MDPI and ACS Style

Joy, A.A.; Ghosh, M.; Fernandes, R.; Clemons, M.J. Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines. Curr. Oncol. 2015, 22, 29-42. https://doi.org/10.3747/co.22.2360

AMA Style

Joy AA, Ghosh M, Fernandes R, Clemons MJ. Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines. Current Oncology. 2015; 22(s1):29-42. https://doi.org/10.3747/co.22.2360

Chicago/Turabian Style

Joy, A.A., M. Ghosh, R. Fernandes, and M.J. Clemons. 2015. "Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines" Current Oncology 22, no. s1: 29-42. https://doi.org/10.3747/co.22.2360

APA Style

Joy, A. A., Ghosh, M., Fernandes, R., & Clemons, M. J. (2015). Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines. Current Oncology, 22(s1), 29-42. https://doi.org/10.3747/co.22.2360

Article Metrics

Back to TopTop